TL;DR
The FDA designated Vitruvias Therapeutics’ recall of one lot of 30-mg thyroid tablets as Class I, the agency’s most serious recall category. The September 29 endocrinology roundup also reported nutritional deficiencies among adolescents taking GLP-1 drugs and updated joint guidance for managing adult type 1 diabetes.
The FDA classified Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets as Class I, its most serious recall category, according to a September 29 endocrinology roundup from MedPage Today. The roundup also covered a study reporting nutritional deficiencies among adolescents taking GLP-1 drugs and updated guidance for managing type 1 diabetes in adults.
The recall concerns one lot of 30-mg thyroid tablets containing levothyroxine and liothyronine. The FDA’s Class I designation identifies the recall as the agency’s most serious category. The source material does not specify the lot number, the reason for the recall, the number of packages involved, or the potential effects for patients.
A study published in Childhood Obesity found that nearly 17% of adolescents taking a GLP-1 drug were diagnosed with at least one nutritional deficiency within the first year of starting treatment. Vitamin D deficiency was the most frequently reported. The roundup does not provide the study’s sample size or establish that the medication caused the deficiencies.
The American Diabetes Association and the European Association for the Study of Diabetes issued updated joint consensus guidance for managing type 1 diabetes in adults, published in Diabetes Care. The supplied report does not detail the recommendations or explain how they differ from previous guidance.
Recall and Treatment Safety Questions
The Class I designation makes the thyroid tablet recall the roundup’s clearest immediate safety development. Patients and clinicians need the affected lot details to determine whether tablets in their possession are included. Those specifics are absent from the supplied report, so the designation alone does not show how many people may be affected or what action any particular patient should take.
The adolescent findings also bear on monitoring during GLP-1 treatment. A reported deficiency rate of nearly 17% within a year may prompt questions about nutritional assessment, especially since vitamin D was the most common deficiency. The result is a study finding, however; it does not establish a cause or show that the same rate applies to all adolescents using these drugs.
Updated adult T1D guidance matters to clinicians reviewing care practices. Without the recommendations themselves, readers cannot assess which decisions or routines may change.
Top picks for "thyroid drug recall"
As an affiliate, we earn on qualifying purchases.
Three Developments in Endocrinology
The report is a roundup of endocrinology news published on September 29, 2026, rather than a single study or announcement. Its items span drug safety, obesity treatment, diabetes care and other endocrine research. The thyroid recall, adolescent nutritional findings and updated adult T1D guidance are three separate developments; the source does not indicate that they are connected.
Other items in the roundup included Roche halting development of the investigational drug emugrobart after a disappointing interim Phase II analysis, and results from several obesity drug comparisons or dosing studies. Some comparisons were indirect or announced by the drugmakers themselves. They provide context on a rapidly developing field, but they do not change the reported facts about the thyroid recall, adolescent study or T1D guidance.
“Updated joint consensus guidelines for managing type 1 diabetes in adults.”
— American Diabetes Association and European Association for the Study of Diabetes
Lot Details and Study Limits
The source does not identify the recalled lot number, explain the recall’s cause, give distribution or quantity figures, or describe any reported injuries. It also does not say what steps the FDA or manufacturer has asked patients, pharmacies or clinicians to take.
For the adolescent GLP-1 study, the roundup gives no sample size, study design details, deficiency screening methods or comparison group. The reported finding does not establish that GLP-1 use caused the deficiencies. The updated T1D guidance is also not described in enough detail to identify specific changes or their intended implementation schedule.
Watch for Recall and Guidance Details
Further reporting or notices from the FDA and Vitruvias Therapeutics may clarify the affected lot, the reason for the recall and any recommended steps for people who may have the tablets. Those details are needed to establish the recall’s practical scope.
The full adolescent study and the updated ADA-EASD consensus document can provide information not included in the roundup, including methods, limitations and specific clinical recommendations. Until those details are available, the reported deficiency rate and the existence of revised guidance are the confirmed points in the supplied material.
Key Questions
What thyroid drug was recalled?
The recall covers a lot of 30-mg levothyroxine-liothyronine tablets made by Vitruvias Therapeutics. The supplied report does not give the lot number.
What does a Class I recall mean in this report?
The report describes Class I as the FDA’s most serious recall classification. It does not provide further details about the specific risk or the recall’s cause.
What did the adolescent GLP-1 study find?
It reported that nearly 17% of adolescents taking a GLP-1 drug were diagnosed with at least one nutritional deficiency within the first year. Vitamin D deficiency was most frequent. The report does not establish that the medication caused the deficiencies.
Who issued the updated type 1 diabetes guidance?
The American Diabetes Association and the European Association for the Study of Diabetes issued updated joint consensus guidance for managing type 1 diabetes in adults. The roundup does not summarize its recommendations.
Source: rss
